KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity (2018 - 2022)

TherapeuticsMD (TXMD) has disclosed Debt to Equity for 7 consecutive years, with -$1.94 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Debt to Equity rose 40.44% year-over-year to -$1.94, compared with a TTM value of -$1.94 through Sep 2022, up 40.44%, and an annual FY2021 reading of -$2.01, down 4.91% over the prior year.
  • Debt to Equity was -$1.94 for Q3 2022 at TherapeuticsMD, up from -$3.48 in the prior quarter.
  • Across five years, Debt to Equity topped out at $23.98 in Q2 2019 and bottomed at -$19.41 in Q1 2021.
  • Average Debt to Equity over 5 years is -$0.43, with a median of -$1.98 recorded in 2021.
  • Peak annual rise in Debt to Equity hit 2711.34% in 2019, while the deepest fall reached 1777.3% in 2019.
  • Year by year, Debt to Equity stood at $0.75 in 2018, then skyrocketed by 2711.34% to $21.15 in 2019, then plummeted by 109.06% to -$1.92 in 2020, then fell by 4.91% to -$2.01 in 2021, then rose by 3.57% to -$1.94 in 2022.
  • Business Quant data shows Debt to Equity for TXMD at -$1.94 in Q3 2022, -$3.48 in Q2 2022, and -$1.44 in Q1 2022.